Elixophyllin

Name: Elixophyllin

What should I avoid while taking Elixophyllin (theophylline)?

Avoid eating foods that are high in fat within 1 hour before or after taking theophylline.

This medication may impair your thinking or reactions. Be careful if you drive or do anything that requires you to be alert.

Elixophyllin (theophylline) side effects

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Stop using theophylline and call your doctor at once if you have a serious side effect such as:

  • severe or continued vomiting;

  • rapid or uneven heartbeats;

  • seizure (convulsions);

  • confusion, tremors or shaking;

  • nausea and vomiting, severe headache, rapid heart rate;

  • low potassium (confusion, uneven heart rate, extreme thirst, increased urination, leg discomfort, muscle weakness or limp feeling); or

  • high blood sugar (increased thirst, increased urination, hunger, dry mouth, fruity breath odor, drowsiness, dry skin, blurred vision, weight loss).

Less serious side effects may include:

  • stomach pain, diarrhea, upset stomach;

  • headache;

  • sweating;

  • sleep problems (insomnia); or

  • feeling restless, nervous, or irritable;

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What other drugs will affect Elixophyllin (theophylline)?

Sometimes it is not safe to use certain drugs at the same time. Some medicines can affect how theophylline works, which could make it less effective or cause side effects. Theophylline could also affect how other medicines work, making them less effective or causing side effects.

Many drugs can interact with theophylline and not all possible interactions are listed in this medication guide. Tell your doctor about all medications you use, start using, or stop using during your treatment with theophylline, especially:

  • cimetidine (Tagamet);

  • fluvoxamine (Luvox);

  • interferon alfa (Intron A, Rebetron, Alferon, Infergen, Pegasys, PegIntron, Sylatron);

  • lithium (Eskalith, Lithobid);

  • ticlopidine (Ticlid);

  • an antibiotic, or medication to treat tuberculosis;

  • heart or blood pressure medication, such as propranolol (Inderal, InnoPran);

  • heart rhythm medication such as mexiletine (Mexitil) or propafenone (Rythmol);

  • medication to treat gout or kidney stones;

  • a sedative such as Valium; or

  • seizure medication.

This list is not complete and many other drugs can interact with theophylline. This includes prescription, over-the-counter, vitamin, and herbal products. Keep a list of all your medicines and show it to any healthcare provider who treats you.

Precautions While Using Elixophyllin

It is very important that your doctor check the progress of you or your child at regular visits, especially for the first few weeks after you begin using this medicine. Blood tests may be needed to check for unwanted effects.

A change in your usual behavior or physical well-being may affect the way this medicine works in your body. Tell your doctor if you or your child:

  • Have had a fever of 102 degrees F or higher for at least 24 hours or more.
  • Have started or stopped smoking tobacco or marijuana in the last few weeks.
  • Have started or stopped taking another medicine in the last few weeks.
  • Have changed your diet in the last few weeks.

Stop using this medicine and check with your doctor right away if you or your child have the following symptoms while using this medicine: nausea or vomiting that continues, headaches, trouble with sleeping, seizures, or irregular heartbeats.

Do not stop or change the dose of this medicine without checking first with your doctor.

Before you have any medical tests, tell the medical doctor in charge that you or your child are using this medicine. The results of some tests may be affected by this medicine.

This medicine may add to the central nervous system (CNS) stimulant effects of caffeine-containing foods or beverages such as chocolate, cocoa, tea, coffee, and cola drinks. Avoid eating or drinking large amounts of these foods or beverages while using this medicine. If you have questions about this, check with your doctor.

Do not take other medicines unless they have been discussed with your doctor. This includes prescription or nonprescription (over-the-counter [OTC]) medicines for appetite control, asthma, colds, cough, hay fever, or sinus problems, and herbal (e.g., St. John's wort) or vitamin supplements.

Elixophyllin Description

Theophylline is structurally classified as a methylxanthine. It occurs as a white, odorless, crystalline powder with a bitter taste. Anhydrous theophylline has the chemical name 1H-Purine- 2,6-dione, 3,7-dihydro-1,3-dimethyl-, and is represented by the following structural formula:

The molecular formula of anhydrous theophylline is C7H8N4O2 with a molecular weight of 180.17. 

Elixophyllin Elixir (Theophylline Oral Solution, USP) is available as a liquid intended for oral administration, containing 80 mg of theophylline anhydrous and 20% alcohol in each 15 mL (tablespoonful).

Elixophyllin Elixir (Theophylline Oral Solution, USP) also contains the following inactive ingredients: anhydrous citric acid, glycerin, saccharin sodium, artificial tutti fruiti flavor #051880A, FD&C red #40 and purified water. Elixophyllin Elixir (Theophylline Oral Solution, USP) has a pH of 3.0-4.0.

Indications and Usage for Elixophyllin

Theophylline is indicated for the treatment of the symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases, e.g., emphysema and chronic bronchitis.

Elixophyllin Dosage and Administration

General Considerations:

The steady-state peak serum theophylline concentration is a function of the dose, the dosing interval, and the rate of theophylline absorption and clearance in the individual patient. Because of marked individual differences in the rate of theophylline clearance, the dose required to achieve a peak serum theophylline concentration in the 10-20 mcg/mL range varies fourfold among otherwise similar patients in the absence of factors known to alter theophylline clearance (e.g., 400-1600 mg/day in adults <60 years old and 10-36 mg/kg/day in children 1-9 years old). For a given population there is no single theophylline dose that will provide both safe and effective serum concentrations for all patients. Administration of the median theophylline dose required to achieve a therapeutic serum theophylline concentration in a given population may result in either sub-therapeutic or potentially toxic serum theophylline concentrations in individual patients. For example, at a dose of 900 mg/d in adults <60 years or 22 mg/kg/d in children 1-9 years, the steady state peak serum theophylline concentration will be <10 mcg/mL in about 30% of patients, 10-20 mcg/mL in about 50% and 20-30 mcg/mL in about 20% of patients. The dose of theophylline must be individualized on the basis of peak serum theophylline concentration measurements in order to achieve a dose that will provide maximum potential benefit with minimal risk to adverse effects.

Transient caffeine-like adverse effects and excessive serum concentrations in slow metabolizers can be avoided in most patients by starting with a sufficiently low dose and slowly increasing the dose, if judged to be clinically indicated, in small increments (See Table V). Dose increases should only be made if the previous dosage is well tolerated and at intervals of no less than 3 days to allow serum theophylline concentrations to reach the new steady state. Dosage adjustment should be guided by serum theophylline concentration measurement (see PRECAUTIONS, Laboratory Tests and DOSAGE AND ADMINISTRATION, Table VI). Health care providers should instruct patients and care givers to discontinue any dosage that causes adverse effects, to withhold the medication until these symptoms are gone and to then resume therapy at a lower, previously tolerated dosage (see WARNINGS).

If the patient’s symptoms are well controlled, there are no apparent adverse effects, and no intervening factors that might alter dosage requirements (see WARNINGS and PRECAUTIONS), serum theophylline concentrations should be monitored at 6 month intervals for rapidly growing children and at yearly intervals for all others. In acutely ill patients, serum theophylline concentrations should be monitored at frequent intervals, e.g., every 24 hours.

Theophylline distributes poorly into body fat, therefore, mg/kg dose should be calculated on the basis of ideal body weight.

Table V contains theophylline dosing titration schema recommended for patients in various age groups and clinical circumstances. Table VI contains recommendations for theophylline dosage adjustment based upon serum theophylline concentrations. Application of these general dosing recommendations to individual patients must take into account the unique clinical characteristics of each patient. In general, these recommendations should serve as the upper limit for dosage adjustments in order to decrease the risk of potentially serious adverse events associated with unexpected large increases in serum theophylline concentration.

Table V. Dosing initiation and titration (as anhydrous theophylline).*

A. Infants <1 year old.

  1. Initial Dosage.

    1. Premature Neonates:

      1. < 24 days postnatal age; 1.0 mg/kg every 12 hr

      2. ≥  24 days postnatal age; 1.5 mg/kg every 12 hr

    2. Full term infants and infants up to 52 weeks of age:

      Total daily dose (mg) = [(0.2 x  age in weeks)+5.0] x  (Kg body Wt).

      1. Up to age 26 weeks; divide dose into 3 equal amounts administered at 8 hour intervals.

      2. >26 weeks of age; divide dose into 4 equal amounts administered at 6 hour intervals.

  2. Final Dosage.Adjusted to maintain a peak steady state serum theophylline concentration of 5-10 mcg/ml in neonates and 10-15 mcg/mL in older infants (see Table VI). Since the time required to reach steady-state is a function of theophylline half-life, up to 5 days may be required to achieve steady state in a premature neonate, while only 2-3 days may be required in a 6 month old infant without other risk factors for impaired clearance in the absence of a loading dose. If a serum theophylline concentration is obtained before steady state is achieved, the maintenance dose should not be increased, even if the serum theophylline concentration is <10 mcg/mL.

B. Children (1-15 years) and adults (16-60 years) without risk factors for impaired clearance.
Titration Step Children < 45 kg Children > 45 kg and adults
1. Starting Dosage 12-14 mg/kg/day up to
a maximum of 300 mg/day
divided Q4-6 hrs*
300 mg/day divided Q6-8 hrs* 
2. After 3 days, if
tolerated, increase
dose to:
16 mg/kg/day up to a
maximum of 400 mg/day
divided Q4-6 hrs*
400 mg/day divided Q6-8 hrs*
3. After 3 more days,
if tolerated, increase
dose to:
20 mg/kg/day
up to a maximum
of 600 mg/day
divided Q4-6 hrs*
600 mg/day divided Q6-8 hrs*

C. Patients With Risk Factors For Impaired Clearance, The Elderly (>60 Years), And Those In Whom It Is Not Feasible To Monitor Serum Theophylline Concentrations:

In children 1-15 years of age, the final theophylline dose should not exceed 16 mg/kg/day up to a maximum of 400 mg/day in the presence of risk factors for reduced theophylline clearance (see WARNINGS) or if it is not feasible to monitor serum theophylline concentrations.

In adolescents ≥16 years and adults, including the elderly, the final theophylline dose should not exceed 400 mg/day in the presence of risk factors for reduced theophylline clearance (see WARNINGS) or if it is not feasible to monitor serum theophylline concentrations.

D. Loading Dose for Acute Bronchodilatation:

An inhaled beta-2 selective agonist, alone or in combination with a systemically administered corticosteroid, is the most effective treatment for acute exacerbations of reversible airways obstruction. Theophylline is a relatively weak bronchodilator, is less effective than an inhaled beta-2 selective agonist and provides no added benefit in the treatment of acute bronchospasm. If an inhaled or parenteral beta agonist is not available, a loading dose of an oral immediate release theophylline can be used as a temporary measure. A single 5 mg/kg dose of theophylline, in a patient who has not received any theophylline in the previous 24 hours, will produce an average peak serum theophylline concentration of 10 mcg/mL (range 5-15 mcg/mL). If dosing with theophylline is to be continued beyond the loading dose, the guidelines in Sections A.1.b., B.3, or C., above, should be utilized and serum theophylline concentration monitored at 24 hour intervals to adjust final dosage.

* Patients with more rapid metabolism, clinically identified by higher than average dose requirements, should receive a smaller dose more frequently to prevent breakthrough symptoms resulting from low trough concentrations before the next dose. A reliably absorbed slow-release formulation will decrease fluctuations and permit longer dosing intervals.

Table VI. Dosage adjustment guided by serum theophylline concentration.
Peak Serum Concentration Dosage Adjustment
¶ Dose reduction and/or serum theophylline concentration measurement is indicated whenever adverse effects are present, physiologic abnormalities that can reduce theophylline clearance occur (e.g., sustained fever), or a drug that interacts with theophylline is added or discontinued (see WARNINGS).
<9.9 mcg/mL If symptoms are not controlled and current dosage is tolerated, increase dose about 25%. Recheck serum concentration after three days for further dosage adjustment.
10 - 14.9 mcg/mL If symptoms are controlled and current dosage is tolerated, maintain dose and recheck serum concentration at 6-12 month intervals.¶ If symptoms are not controlled and current dosage is tolerated consider adding additional medication(s) to treatment regimen.
15-19.9 mcg/mL Consider 10% decrease in dose to provide greater margin of safety even if current dosage is tolerated.¶
20-24.9 mcg/mL Decrease dose by 25% even if no adverse effects are present. Recheck serum concentration after 3 days to guide further dosage adjustment.
25-30 mcg/mL Skip next dose and decrease subsequent doses at least 25% even if no adverse effects are present. Recheck serum concentration after 3 days to guide further dosage adjustment. If symptomatic, consider whether overdose treatment is indicated (see recommendations for chronic overdosage).
>30 mcg/mL Treat overdose as indicated (see recommendations for chronic overdosage). If theophylline is subsequently resumed, decrease dose by at least 50% and recheck serum concentration after 3 days to guide further dosage adjustment.

For the Consumer

Applies to theophylline: oral capsule, oral capsule extended release, oral capsule extended release 12 hr, oral capsule extended release 24 hr, oral elixir, oral solution, oral syrup, oral tablet, oral tablet enteric coated, oral tablet extended release, oral tablet extended release 12 hr, oral tablet extended release 24 hr

Other dosage forms:

  • intravenous solution

Along with its needed effects, theophylline (the active ingredient contained in Elixophyllin) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking theophylline:

Incidence not known
  • Chest pain or discomfort
  • dizziness
  • fainting
  • fast, slow, or irregular heartbeat
  • increase in urine volume
  • lightheadedness
  • persistent vomiting
  • pounding or rapid pulse
  • seizures
  • shakiness

Get emergency help immediately if any of the following symptoms of overdose occur while taking theophylline:

Symptoms of overdose
  • Abdominal or stomach pain
  • blurred vision
  • confusion
  • confusion about identity, place, and time
  • dark-colored urine
  • decrease in frequency of urination
  • decreased urine
  • diarrhea
  • difficulty in passing urine (dribbling)
  • dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position
  • dry mouth
  • fast, pounding, or irregular heartbeat or pulse
  • fever
  • increased thirst
  • irregular heartbeat
  • loss of appetite
  • mood changes
  • muscle cramps or spasms
  • muscle pain or stiffness
  • nausea or vomiting
  • nervousness
  • numbness or tingling in the hands, feet, or lips
  • pain or discomfort in the arms, jaw, back, or neck
  • painful urination
  • shakiness in the legs, arms, hands, or feet
  • shortness of breath
  • sweating
  • unusual tiredness or weakness
  • vomiting of blood or material that looks like coffee grounds

Some side effects of theophylline may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Incidence not known
  • Headache
  • irritability
  • restlessness
  • sleeplessness
  • trouble sleeping
  • unable to sleep

Theophylline Breastfeeding Warnings

Theophylline is excreted into human milk and may cause irritability or other signs of mild toxicity. The concentration of theophylline in breast milk is approximately equivalent to the maternal serum concentration. The manufacturer states that serious adverse effects in the infant are unlikely unless the mother has toxic serum theophylline concentrations. The American Academy of Pediatrics considers theophylline to be compatible with breast-feeding.

In a study of five women given aminophylline, theophylline was detected in milk with a milk:serum ratio of 0.61 to 0.87. The peak milk concentration occurred between one and three hours after ingestion of the dose. Irritability was reported in one infant whose mother took aminophylline. Adverse effects were not reported in the infants of the other women participating in this study. Exposure to the infant can be minimized by administering nursing prior to administration of theophylline to avoid peak milk concentrations.

Administrative Information

LactMed Record Number

253

Last Revision Date

20130907

Disclaimer

Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

(web3)